RxDoctor Payments Data

Ashley Blackwood

Family · Little Rock, ARNPI 1295276285

Payments from drug & device makers

$2,906in general payments, 2019–2025

Across 180 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$712
  • GSK$412
  • Pfizer$309
  • Lilly USA, LLC$262
  • Novo Nordisk$200
  • AstraZeneca$166
  • plus $845 from 20 others

What the payments were for

  • Food & beverage$2,906100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,906 in reported general payments places this provider in the 85th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$40,094
Medicare patients
325
Services billed
3,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,075
EliquisApixaban23$13,453
OzempicSemaglutide13$12,293
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,645
SymbicortBudesonide/Formoterol Fumarate14$3,508
SynthroidLevothyroxine Sodium24$1,131
Atorvastatin Calcium117$1,039
Levothyroxine Sodium117$858
Albuterol Sulfate HfaAlbuterol Sulfate13$566
Amlodipine Besylate80$530
Pravastatin Sodium29$525
Amitriptyline Hcl16$494
Rosuvastatin Calcium62$493
Fluticasone Propionate37$453
Potassium Chloride31$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$412$25,07533 claims
PfizerEliquis$309$13,45323 claims
Novo NordiskOzempic$200$12,29313 claims
AstraZenecaSymbicort$166$3,50814 claims
AbbVieSynthroid$712$1,13124 claims
Almatica Pharma LLCSertraline Hcl$14$21023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,103 family providers in Arkansas.

Other family in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →